Hansoh Pharma gains approval for HS-10561, HS-20093 advances

** Hansoh Pharmaceutical Group (HKEX:3692) announced significant progress in its drug development pipeline. The National Medical Products Administration (NMPA) of China granted clinical trial approval for HS-10561 capsules, a Category 1 small molecule Bruton's tyrosine kinase inhibitor (BTKi) developed with Guangzhou Lupeng Pharmaceutical Co., Ltd. The trials will investigate its efficacy in treating chronic spontaneous urticaria. Simultaneously, the NMPA designated Hansoh's self-developed B7-H3-targeted antibody-drug conjugate (ADC) HS-20093 as a Breakthrough-Therapy-Designated Drug for treating osteosarcoma patients who have progressed after at least two prior lines of therapy. HS-20093, already designated for extensive-stage small-cell lung cancer (ES-SCLC), is undergoing multiple clinical trials for lung, head, and neck cancers. These approvals mark crucial steps for Hansoh in expanding its oncology and immunology portfolios.